Aquestive Therapeutics, Inc.

AQST

US03843E1047

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.07 ^USD	+3.56%		-0.85%	+101.49%

Apr. 12	Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology	CI
Apr. 11	Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	MT

Aquestive Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

March 05, 2024 at 05:05 pm EST

Aquestive Therapeutics, Inc. provided earnings guidance for the year 2024. For the year, the company expects total revenue to be in range of $48 million to $51 million.

Latest news about Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology	Apr. 12	CI
Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target	Apr. 11	MT
Aquestive Therapeutics Files $250 Million Mixed Shelf	Apr. 03	MT
Aquestive Therapeutics, Inc. Appoints Abigail Jenkins to Board of Directors, Effective April 1, 2024	Apr. 01	CI
Raymond James Initiates Aquestive Therapeutics With Outperform Rating, $7 Price Target	Mar. 28	MT
Top Midday Decliners	Mar. 20	MT
Sector Update: Health Care Stocks Steady Premarket Wednesday	Mar. 20	MT
Wall Street Set to Open Flat as Investors Look Toward Fed Decision; Oil Prices Drop Sharply	Mar. 20	MT
Top Premarket Decliners	Mar. 20	MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering; Shares Slump Premarket	Mar. 20	MT
Aquestive Therapeutics Prices $75 Million Common Stock Offering	Mar. 20	MT
Aquestive Therapeutics Proposes Public Stock Offering -- Shares Drop	Mar. 19	MT
H.C. Wainwright Raises Price Target on Aquestive Therapeutics to $9 From $7, Maintains Buy Rating	Mar. 18	MT
JMP Securities Adjusts Price Target on Aquestive Therapeutics to $10 From $8, Maintains Market Outperform Rating	Mar. 15	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Mar. 15	MT
Aquestive Therapeutics' Anaphylm Demonstrates Faster Maximum Concentration Reach in Phase 3 Trial	Mar. 14	MT
Aquestive Therapeutics, Inc. Releases Positive Topline Clinical Data from Its Phase 3 Pivotal Pharmacokinetic (PK) Clinical Study of Anaphylm (Epinephrine) Sublingual Film and Findings from the FDA Type C meeting	Mar. 14	CI
HC Wainwright Adjusts Price Target on Aquestive Therapeutics to $7 From $6, Maintains Buy Rating	Mar. 11	MT
Wedbush Lifts Aquestive Therapeutics' PT to $9 From $4 After Model Adjustments, Keeps Outperform Rating	Mar. 07	MT
Transcript : Aquestive Therapeutics, Inc., Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Aquestive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Earnings Flash (AQST) AQUESTIVE THERAPEUTICS Posts Q4 Revenue $13.2M, vs. Street Est of $11.6M	Mar. 05	MT
Aquestive Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 05	CI
Aquestive Therapeutics, Inc. Provides Earnings Guidance for the Year 2024	Mar. 05	CI
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm (epinephrine) Sublingual Film	Dec. 05	CI

Chart Aquestive Therapeutics, Inc.

Duration

Period

More charts

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Companyâs Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.

Sector

Pharmaceuticals

Calendar

2024-05-06 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Aquestive Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.07 USD

Average target price

9 USD

Spread / Average Target

+121.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AQUESTIVE THERAPEUTICS, INC.	+101.49%	368M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals